Big Pharma is getting leaner and meaner. Just ask the 100,000 workers laid off since 9/11.
Sep 1, 2007
By:
Walter Armstrong
Ever since Jeffrey Kindler rocked our world last December with the news that Pfizer was cutting its sales force by 10,000, we've been waiting for all the other behemoths' shoes to drop. While no precise domino effect has occurred, downsizing, particularly on the sales side, is very much pharma's strategy du jour.
|
With a new wave of "resistant to resistance" HIV drugs, a record of consistent innovation, and a dynamic partnership with AIDS activists, J&J's little company is in it to win it. And end it.
Jul 30, 2007
By:
Walter Armstrong
Tibotec is set to launch a second revolution in HIV treatment—Âand make a run at Glaxo, BMS, and Abbott, the longtime market kingpins
|
|
Turnover in the top 10 has new CEOs racing to reinvent the way their companies do business. But who has the courage to lead the industry itself back to greatness?
Jul 3, 2007
By:
Walter Armstrong
It's bittersweet being one of the leaders of an industry that is not sustainable," a top pharma CEO recently told Carolyn Buck Luce, Ernst & Young's global pharmaceutical sector leader. Bittersweet is a poignant word for a hard-driving exec to issue.
|
Jul 3, 2007
By:
Walter Armstrong
Or: No news is good news--for everyone but us reporters
|
Think you know the story? Take the test to see what you missed.
Jul 3, 2007
By:
Walter Armstrong
All hell broke loose on May 21 when the New England Journal of Medicine released Cleveland Clinic cardiologist Dr. Steven Nissen's meta-analysis of 42 studies of Avandia, showing a 43 percent increased risk of heart attack.
|
|
Pharma's new commercialization strategy is, uh, in the works. But what did you expect? Getting it right takes time.
Jun 1, 2007
By:
Joanna Breitstein, Walter Armstrong
It was like the end of the arms race last November when Pfizer announced it was slashing its national sales force by 20 percent. Coolly downplayed as cost-cutting by new CEO Jeffrey Kindler, the stunning move was met by industry insiders, Wall Street analysts, and the media with one humongous collective sigh of relief. Big Pharma was seen as having grown dangerously addicted to the detailing game over the past decade, with the top firms plowing more and more of their blockbuster profits into trying to keep up with Pfizer's "flood the zone" strategy and with less and less to show for it.
|
|
PharmExec Blog
Follow Us
RSS
Bookstore
